Evidence map›Paper›PMID 18691423›Full record

ArticleBMC cancer2008

Imagable 4T1 model for the study of late stage breast cancer.

Kai Tao, Min Fang, Joseph Alroy, G Gary Sahagian

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 273 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
273citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

273 citing papers in PubMed, 1 synthesis or guideline pooled it, 516 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Chlorogenic acid suppresses angiogenesis in 4T1 breast tumorsResearch in pharmaceutical sciences · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Exploring the Anticancer Potential ofCurrent issues in molecular biology · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Immuno-PET Imaging of CD93 Expression withMolecular pharmaceutics · 2024
    Article

213 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Kai TaoDepartment of Physiology, Tufts University School of Medicine, Boston, Massachusetts 02111, USA. kai.tao@tufts.edu
Min Fang
Joseph Alroy
G Gary Sahagian
Tufts University · USTufts Medical Center · US

Funding

DEMONSTRATION OF CATHEPSIN FUNCTION IN TUMOR METASTASISR01CA066575 · NCI · TUFTS UNIVERSITY BOSTON · PI SAHAGIAN, GARABED GARY · 1997 to 2000
$280k
NCI NIH HHS 5R01CA66575
6 · The paper itself

Abstract

backgroundThe 4T1 mouse mammary tumor cell line is one of only a few breast cancer models with the capacity to metastasize efficiently to sites affected in human breast cancer. Here we describe two 4T1 cell lines modified to facilitate analysis of tumor growth and metastasis and evaluation of gene function in vivo. New information regarding the involvement of innate and acquired immunity in metastasis and other characteristics of the model relevant to its use in the study of late stage breast cancer are reported.

methodsThe lines were engineered for stable expression of firefly luciferase to allow tracking and quantitation of the cells in vivo. Biophotonic imaging was used to characterize growth and metastasis of the lines in vivo and an improved gene expression approach was used to characterize the basis for the metastatic phenotype that was observed.

resultsGrowth of cells at the primary site was biphasic with metastasis detected during the second growth phase 5-6 weeks after introduction of the cells. Regression of growth, which occurred in weeks 3-4, was associated with extensive necrosis and infiltration of leukocytes. Biphasic tumor growth did not occur in BALB/c SCID mice indicating involvement of an acquired immune response in the effect. Hematopoiesis in spleen and liver and elevated levels of circulating leukocytes were observed at week 2 and increased progressively until death at week 6-8. Gene expression analysis revealed an association of several secreted factors including colony stimulatory factors, cytokines and chemokines, acute phase proteins, angiogenesis factors and ECM modifying proteins with the 4T1 metastatic phenotype. Signaling pathways likely to be responsible for production of these factors were also identified.

conclusionThe production of factors that stimulate angiogenesis and ECM modification and induce hematopoiesis, recruitment and activation of leukocytes suggest that 4T1 tumor cells play a more direct role than previously appreciated in orchestrating changes in the tumor environment conducive to tumor cell dissemination and metastasis. The new cell lines will greatly facilitate the study of late stage breast and preclinical assessment of cancer drugs and other therapeutics particularly those targeting immune system effects on tumor metastasis.

Indexed as

AnimalsBreast NeoplasmsCell Line, TumorDiagnostic ImagingFemaleGene Expression Regulation, NeoplasticHumansMammary Neoplasms, AnimalMiceMice, Inbred BALB CMice, NudeMice, SCIDNecrosisNeoplasm MetastasisNeovascularization, Pathologic

Identifiers

PMID18691423
PMCPMC2529338
OpenAlexW2159490365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.